EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSJJAG00000013074
Gene Symbol: SCN2A
3 Cross references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSJJAG00000022775
Gene Symbol: SCN3A
3 Cross references
167 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSJJAG00000012708
Gene Symbol: SCN4A
3 Cross references
193 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSJJAG00000024222
Gene Symbol: SCN7A
3 Cross references
86 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSJJAG00000018047
Gene Symbol: SCN8A
3 Cross references
274 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSJJAG00000023830
Gene Symbol: SCN9A
3 Cross references
110 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-4

Ensembl ID : ENSJJAG00000018895
Gene Symbol: LOC101600796
3 Cross references
564 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSJJAG00000010953
Gene Symbol: LOC101607470
2 Cross references
298 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSJJAG00000021668
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSJJAG00000023573
Gene Symbol: SLC18A2
3 Cross references
223 Possible Orthologues:

Solute Carrier Family 22 Member 12

Ensembl ID : ENSJJAG00000020785
Gene Symbol: SLC22A12
3 Cross references
470 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSJJAG00000009093
Gene Symbol: SLC22A6
3 Cross references
490 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).